Drug delivering technology for endovascular management of infrainguinal peripheral artery disease

JACC: Cardiovascular Interventions

Volumn 7, Issue 8, 2014, Pages 827-839

  Sarode, Karan ^a   Spelber, David A ^b   Bhatt, Deepak L ^c   Mohammad, Atif ^a   Prasad, Anand ^b   Brilakis, Emmanouil S ^a   Banerjee, Subhash ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

drug coated balloons; drug coated stents; peripheral artery disease; review

Indexed keywords

PACLITAXEL; RAPAMYCIN; EVEROLIMUS; ZOTAROLIMUS; BIOMATERIAL; CARDIOVASCULAR AGENT; DRUG CARRIER;

DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ENDOVASCULAR SURGERY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; IN-STENT RESTENOSIS; INFRAPOPLITEAL PERIPHERAL ARTERY DISEASE; META ANALYSIS; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNITED STATES; ARTICLE; BARE METAL STENT; BIODEGRADABLE IMPLANT; CRITICAL LIMB ISCHEMIA; DIRECTIONAL ATHERECTOMY; DOUBLE BLIND PROCEDURE; DRUG COATED BALLOON; DRUG DELIVERY DEVICE; EVENT FREE SURVIVAL; INFRAINGUINAL PERIPHERAL ARTERY DISEASE; LEG REVASCULARIZATION; LIMB SALVAGE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); ADVERSE EFFECTS; ANIMAL; CENTRAL VENOUS CATHETER; DEVICES; DRUG EFFECTS; FEMORAL ARTERY; PATHOPHYSIOLOGY; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS; RISK FACTOR; STENOSIS, OCCLUSION AND OBSTRUCTION; TREATMENT OUTCOME; VASCULAR PATENCY;

ABSORBABLE IMPLANTS; ANIMALS; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; DRUG CARRIERS; DRUG-ELUTING STENTS; ENDOVASCULAR PROCEDURES; FEMORAL ARTERY; HUMANS; PERIPHERAL ARTERIAL DISEASE; POPLITEAL ARTERY; PROSTHESIS DESIGN; RISK FACTORS; TREATMENT OUTCOME; VASCULAR ACCESS DEVICES; VASCULAR PATENCY;

EID: 84906347752     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.05.008     Document Type: Review

References (75)

1. R.C. Pasternak, M.H. Criqui, E.J. Benjamin for the American Heart Association Atherosclerotic Vascular Disease Conference: Writing Group I: epidemiology Circulation 109 2004 2605 2612
2. K.K. May, P.A. Robless, H.R. Sidhu, B.S. Chua, and P. Ho Limb salvage in patients with peripheral arterial disease managed by endovascular first approach Vasc Endovasc Surg 48 2014 129 133
3. M.D. Dake, G.M. Ansel, M.R. Jaff for the Zilver PTX Investigators Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies J Am Coll Cardiol 61 2013 2417 2427
4. Zeller T. Drug coated balloons: hope or hype? Endovascular Today 2012. Available at: http://evtoday.com/2012/08/drug-coated-balloons-hope-or-hype/. Accessed December 16, 2013.
5. M. Fusaro, S. Cassese, and G. Ndrepepa et al. Paclitaxel-coated balloon or primary bare nitinol stent for revascularization of femoropopliteal artery: a meta-analysis of randomized trials versus uncoated balloon and an adjusted indirect comparison Int J Cardiol 168 2013 4002 4009
6. S. Cassese, R.A. Byrne, and I. Ott et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials Circ Cardiovasc Interv 5 2012 582 589
7. G.G. Biondi-Zoccai, G. Sangiorgi, and M. Lotrionte et al. Infragenicular stent implantation for below-the-knee atherosclerotic disease: clinical evidence from an international collaborative meta-analysis on 640 patients J Endovasc Ther 16 2009 251 260
8. G.A. Antoniou, N. Chalmers, and K. Kanesalingham et al. Meta-analysis of outcomes of endovascular treatment of infrapopliteal occlusive disease with drug-eluting stents J Endovasc Ther 20 2013 131 144
9. X. Yang, X. Lu, K. Ye, X. Li, J. Qin, and M. Jiang Systematic review and meta-analysis of balloon angioplasty versus primary stenting in the infrapopliteal disease Vasc Endovasc Surg 48 2014 18 26
10. M. Fusaro, S. Cassese, and G. Ndrepepa et al. Drug-eluting stents for revascularization of infrapopliteal arteries: updated meta-analysis of randomized trials J Am Coll Cardiol Int 6 2013 1284 1293
11. M.G. Davies, and J.E. Anaya-Ayala Endovascular techniques in limb salvage: cutting, cryo, brachy, and drug-eluting balloons Methodist Debakey Cardiovasc J 9 2013 69 72
12. Y.G. Kim, I.Y. Oh, and Y.W. Kwon et al. Mechanism of edge restenosis after drug-eluting stent implantation: angulation at the edge and mechanical properties of the stent Circ J 77 2013 2928 2935
13. J. Grimm, S. Muller-Hulsbeck, T. Jahnke, C. Hilbert, J. Brossmann, and M. Heller Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions J Vasc Interv Radiol 12 2001 935 942
14. Banerjee S. Peripheral arterial disease: missed opportunity for cardiovascular intervention. Paper presented at: National Interventional Council; April 12-14 2013; Kolkata, India.
15. M.S. Conte Diabetic revascularization: endovascular versus open bypass-do we have the answer? Semin Vasc Surg 2 2012 108 114
16. E.J. Armstrong, S. Singh, and G.D. Singh et al. Angiographic characteristics of femoropopliteal in-stent restenosis: association with long-term outcomes after endovascular intervention Catheter Cardiovasc Interv 82 2013 1168 1174
17. A. Schmidt, M. Piorkowski, and M. Werner et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome J Am Coll Cardiol 58 2011 1105 1109
18. K. Chitkara, and K. Pujara Drug-eluting stents in acute coronary syndrome: is there a risk of stent thrombosis with second-generation stents? Eur J Cardiovasc Med 1 2010 20 24
19. S.H. Duda, T.C. Poerner, and B. Wiesinger et al. Drug-eluting stents: potential applications for peripheral arterial occlusive disease J Vasc Interv Radiol 14 2003 291 301
20. Banerjee S. Nano and microparticle drug delivery: how it will play a role in peripheral arterial interventions. Paper presented at: The Veith Symposium; November 19-23 2013; New York, NY.
21. Cook Medical Cook Zilver PTX Drug Eluting Stent Owner's Manual Version IFU0093-4. Limerick, Ireland: Cook Medical 2014 3
22. J.A. Ormiston, and P.W. Serruys Bioabsorbable coronary stents Circ Cardiovasc Interv 2 2009 255 260
23. S.H. Duda, M. Bosiers, and J. Lammer et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial J Endovasc Ther 13 2006 701 710
24. G. Nakazawa, F. Otsuka, and M. Nakano et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
25. S. Gabardi, and S.A. Baroletti Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology Pharmacotherapy 30 2010 1044 1056
26. J. Lammer, M. Bosiers, and T. Zeller et al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease J Vasc Surg 54 2011 394 401
27. Dake MD, Ansel GM. 3-Year results from the Zilver PTX drug eluting stent (DES) trial: are the results durable and how do patterns of restenosis differ. Paper presented at: VEITH Symposium, November 14-18 2012; New York, NY.
28. A. Rastan, K. Brechtel, and H. Krankenberg et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial J Am Coll Cardiol 60 2012 587 591
29. M. Bosiers, D. Scheinert, and P. Peeters et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease J Vasc Surg 55 2012 390 398
30. A.J. Feiring, M. Krahn, L. Nelson, A. Wesolowski, D. Eastwood, and A. Szabo Preventing leg amputations in critical limb ischemia with below-the-knee drug-eluting stents: the PaRADISE (PReventing Amputations using Drug eluting StEnts) trial J Am Coll Cardiol 55 2010 1580 1589
31. M. Bosiers, P. Peeters, O. D'Archambeau for the AMS INSIGHT Investigators AMS INSIGHT-absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis Cardiovasc Intervent Radiol 32 2009 424 435
32. M. Werner, A. Micari, and A. Cioppa et al. Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery J Am Coll Cardiol Intv 7 2014 305 312
33. G. Kassmis, S. Spiliopoulos, K. Katsanos, D. Tsetis, and M.E. Krokidis Bioresorbable scaffolds in peripheral arterial disease Expert Rev Cardiovasc Ther 12 2014 443 450
34. D. Siablis, D. Karnabatidis, K. Katsanos, A. Diamantopoulos, N. Christeas, and G.C. Kagadis Infrapopliteal application of paclitaxel-eluting stents for critical limb ischemia: midterm angiographic and clinical results J Vasc Interv Radiol 18 2007 1351 1361
35. A.V. Finn, M. Joner, and G. Nakazawa et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441
36. R.A. Byrne, M. Joner, F. Alfonso, and A. Kastrati Drug-coated balloon therapy in coronary and peripheral artery disease Nat Rev Cardiol 11 2014 13 23
37. B. Cremers, S. Schmitmeier, Y.P. Clever, G. Gershony, U. Speck, and B. Scheller Inhibition of neo-intimal hyperplasia in porcine coronary arteries utilizing a novel paclitaxel-coated scoring balloon catheter Catheter Cardiovasc Interv 2013 Nov 21 [E-pub ahead of print]
38. V.B. Kolachalama, S.D. Pacetti, and J.W. Franses et al. Mechanisms of tissue uptake and retention in zotarolimus-coated balloon therapy Circulation 127 2013 2047 2055
39. D. Scheinert, S. Duda, and T. Zeller et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization J Am Coll Cardiol Intv 7 2014 10 19
40. G. Tepe, T. Zeller, and T. Albrecht et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg N Engl J Med 358 2008 689 699
41. M. Werk, T. Albrecht, and D.R. Meyer et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial Circ Cardiovasc Interv 5 2012 831 840
42. M. Werk, S. Langner, and B. Reinkensmeier et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial Circulation 13 2008 1358 1365
43. Metzger C. US Trial Update: Levant 2. Paper presented at: Transcatheter Cardiovascular Therapeutics, October 28-November 1 2013; San Francisco, CA.
44. Randomized Trial of IN.PACT (Paclitaxel) Admiral Drug-Eluting Balloon (DEB) vs. Standard Percutaneous Transluminal Angioplasty (PTA) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA). 2012. Available at: http://clinicaltrials.gov/ ct2/show/NCT01566461. Accessed January 3, 2014.
45. FREERIDE Study, Freeway Paclitaxel Coated Balloon Catheter to Treat Peripheral Artery Disease. 2013. Available at: http://clinicaltrials.gov/ct2/ show/NCT01960647. Accessed January 2, 2014.
46. Advance 18PTX Balloon Catheter Study: Treatment of Lesions in Superficial Femoral Artery/Popliteal Artery with a Paclitaxel-coated Balloon. 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT00776906. Accessed January 2, 2014.
47. Randomized Trial of Stenting After Dilation With or Without Paclitaxel Eluting Balloon or Atherectomy in Patients With Symptomatic Peripheral Artery Disease. 2010. Available at: http://clinicaltrials.gov/ct2/show/NCT00986752. Accessed January 2, 2014.
48. ILLUMENATE Pivotal, CVI Drug-Coated Balloon vs. Uncoated Balloon. 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01858428. Accessed March 19, 2014.
49. A. Micari, A. Cioppa, and G. Vadala et al. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry J Am Coll Cardiol Intv 6 2013 282 289
50. F. Liistro, I. Porto, and P. Angioli et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia Circulation 128 2013 615 621
51. Study of IN.PACT Amphirion Drug Eluting Balloon vs. Standard PTA for the Treatment of Below the Knee Critical Limb Ischemia (INPACT-DEEP). 2013. Available at: http://www.clinicaltrials.gov/ct2/show/record/NCT00941733. Accessed January 2, 2014.
52. Medtronic Recalls In.Pact Amphirion DEB for Below-the-Knee Disease Based on Trial Results. 2013. Available at: http://evtoday.com/2013/11/medtronic- recalls-inpact-amphirion-deb-for-btk-disease-based-on-trial-results. Accessed January 2, 2014.
53. Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) Arteries. 2013. Available at: http://clinicaltrials.gov/ ct2/show/NCT01870401. Accessed Nov 23, 2013.
54. E. Stabile, V. Virga, and L. Salemme et al. Drug-eluting balloon for treatment of superficial femoral artery in-stent restenosis J Am Coll Cardiol 60 2012 1739 1742
55. Stabile E. 2-year results of DEB for treatment of ISR. Paper presented at: Leipzig Interventional Course 2014, January 28-31 2014; Leipzig, Germany.
56. Paclitaxel-Coated Versus Uncoated Balloon for Treatment of Below-the-Knee In-Stent-Restenosis. 2013. Available at: http://clinicaltrials.gov/ct2/show/ NCT01398033. Accessed January 2, 2014.
57. Femoral Artery In-Stent Restenosis (FAIR) Trial. 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01305070. Accessed January 2, 2014.
58. Cotavance Paclitaxel-Coated Balloon Versus Uncoated Balloon Angioplasty for Treatment of In-stent Restenosis in SFA and Popliteal Arteries COPA CABANA Study. 2012. Available at: http://clinicaltrials.gov/ct2/show/NCT01594684. Accessed January 2, 2014.
59. Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery (ISAR-PEBIS). 2010. Available at: http://clinicaltrials.gov/ct2/show/NCT01083394. Accessed January 2, 2014.
60. F. Liistro, S. Grotti, and I. Porto et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (Drug Eluting Balloon in Peripheral Intervention for the Superficial Femoral Artery) J Am Coll Cardiol Intv 6 2013 1295 1302
61. S. Banerjee, T.S. Das, and M.S. Abu-Fadel et al. Pilot trial of cryoplasty or conventional balloon post-dilation of nitinol stents for revascularization of peripheral arterial segments: the COBRA trial J Am Coll Cardiol 60 2012 1352 1359
62. Schulte KL. Drug-coated balloons (DCB) in SFA-intervention: clinical program update. Paper presented at: Transcatheter Cardiovascular Therapeutics, October 28-November 1 2013; San Francisco, CA.
63. Legflow Paclitaxel Eluting Balloon (LPEB) with stent placement versus standard percutaneous transluminal angioplasty with stent placement for the treatment of occlusive disease of the superficial femoral artery. 2013. Available at: http://www.controlled-trials.com/ISRCTN47846578. Accessed January 2, 2014.
64. Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease (DEFINITIVE AR). 2013. Available at: http://clinicaltrials.gov/ ct2/show/NCT01366482. Accessed January 2, 2014.
65. Atherectomy and Drug-Coated Balloon Angioplasty in Treatment of Long Infrapopliteal Lesions (ADCAT). 2013. Available at: http://clinicaltrials.gov/ ct2/show/NCT01763476. Accessed January 2, 2014.
66. Photoablative Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis in In-stent Femoropopliteal Obstructions (PHOTOPAC). 2011. Available at: http://clinicaltrials.gov/ct2/show/record/NCT01298947. Accessed March 19, 2014.
67. Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery. 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01728441. Accessed January 2, 2014.
68. Infrapopliteal Drug Eluting Angioplasty Versus Stenting (IDEAS-I). 2013. Available at: http://clinicaltrials.gov/ct2/show/record/NCT01517997. Accessed January 2, 2014.
69. B. Cremers, U. Speck, and N. Kaufels et al. Drug-eluting balloon: very short-term exposure and overlapping Thromb Haemost 101 2009 201 206
70. P. Freyhardt, T. Zeller, and T.J. Kroncke et al. Plasma levels following application of paclitaxel-coated balloon catheters in patients with stenotic or occluded femoropopliteal arteries Rofo 183 2011 448 455
71. J.P. Loh, and R. Waksman Paclitaxel drug-coated balloons: a review of current status and emerging applications in native coronary artery de novo lesions J Am Coll Cardiol Intv 5 2012 1001 1012
72. C.J. Creel, M.A. Lovich, and E.R. Edelman Arterial paclitaxel distribution and deposition Circ Res 86 2000 879 884
73. H. Xu, S. Kona, and L.C. Su et al. Multi-ligand poly(L-lactic-co-glycolic acid) nanoparticles inhibit activation of endothelial cells J Cardiovasc Transl Res 6 2013 570 578
74. M. Dorenkamp, J. Boldt, and A.W. Leber et al. Cost-effectiveness of paclitaxel-coated balloon angioplasty in patients with drug-eluting stent restenosis Clin Cardiol 36 2013 407 413
75. Zeller T. The cost-effectiveness value of DEB in femoro-popliteal revascularization. Paper presented at: Leipzig Interventional Course 2014, January 28-31 2014; Leipzig, Germany.